secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016832
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma Q3 FY2025 net income $4M, revenue up 32% YoY to $18.5M
---------------------------------------------------------------------

- Net income of $4.0M ($0.65 basic / $0.21 diluted EPS) vs net loss of $2.9M a year ago.
- Total net revenue $18.5M, up 32% YoY; ADHD portfolio up 25% to $15.4M, Pediatric up 77% to $3.1M.
- Adjusted EBITDA $3.9M vs $0.9M in Q3 FY2024; operating expenses down 13% YoY.
- Cash $18.2M at March 31, 2025; paid down $2.5M in long-term debt during the quarter.
- Gross margin 69% vs 74% prior year due to higher-cost ADHD inventory from closed Texas facility; expected to normalize.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/0001437749-25-016832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925016832/aytu20250213_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer